BENZNIDAZOLE
PeakSMbenznidazole
NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
BENZNIDAZOLE (benznidazole) is [see microbiology ( )] . First approved in 2017.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benznidazole is an oral nitroimidazole antiparasitic agent approved in 2017 for the treatment of American trypanosomiasis (Chagas disease), a neglected tropical disease caused by Trypanosoma cruzi. The drug works by disrupting parasitic DNA and protein synthesis, making it effective against the protozoan pathogen. It represents a critical therapeutic option for patients in endemic regions of Central and South America.
Peak
Peak lifecycle stage indicates stable commercial operations with mature demand in niche endemic markets; team size likely modest given disease prevalence concentration.
Mechanism of Action
[see Microbiology ( )] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on benznidazole positions you in a mission-driven, neglected tropical disease franchise with strong global health alignment and emerging-market expertise. The peak lifecycle and stable demand provide predictable career progression within a specialized but protected therapeutic niche.
Medical Science LiaisonBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.